The company offers new conjugation technologies, including a patented Lock-Release technology, for the development and manufacture of ADC cancer therapies. They also provide bioconjugation services to enable physicians to treat patients with ADC and anti-cancer therapies. ADC Biotechnology Ltd was founded in 2010 to develop and commercialize next-generation conjugation technologies for the ADC market and is now located at Sterling Pharma Solutions' Deeside facility.